AI Articles and Analysis in Healthcare

The "buy versus build" debate is central to digital transformation, particularly in AI adoption, and hinges on an organization's unique goals and industry context. 

This interview analysis is sponsored by MinIO and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Gilead Sciences, a biopharmaceutical company founded in 1987, has emerged as a leader in the development of innovative therapies for a range of diseases, including HIV, liver diseases, and oncology. With a commitment to advancing the field of medicine, Gilead has increasingly recognized the vital role that AI plays in its operations. Gilead Sciences achieved an annual revenue of approximately $28.3 billion in 2024, driven by its robust portfolio, and employs around 18,000 people globally, reflecting its substantial size and reach within the biotech industry​.

From intelligent sourcing and predictive analytics to automated contract analysis and risk mitigation, AI is enabling procurement teams to focus on strategic activities while delivering significant cost savings and improved supplier relationships.

Unlike other industrial sectors, many healthcare systems and services are embracing the roadblocks in their technological adoption processes. Thoroughly vetting systems is far more critical for most forms of patient care than having the latest and greatest technology. 

In 2020, we wrote about the early but fertile stage of AI development at Johnson and Johnson. Since then, the COVID-19 pandemic and improvements to machine learning have forced important changes in how J&J is using artificial intelligence. 

As life sciences organizations increasingly adopt AI to enhance productivity, streamline workflows, and improve quality, aligning AI initiatives with business objectives and evolving traditional return on investment (ROI) metrics have become essential strategies. These practices not only secure executive buy-in but also ensure sustained success in AI adoption.

As technology advances, the lines between mobile applications and medical devices are blurring in ways that have healthcare leaders, software developers, and regulators alike facing new and unprecedented challenges.